JP2024515936A - Ｃａｓ酵素を用いたマルチプレックス編集 - Google Patents

Ｃａｓ酵素を用いたマルチプレックス編集 Download PDF

Info

Publication number
JP2024515936A
JP2024515936A JP2023556950A JP2023556950A JP2024515936A JP 2024515936 A JP2024515936 A JP 2024515936A JP 2023556950 A JP2023556950 A JP 2023556950A JP 2023556950 A JP2023556950 A JP 2023556950A JP 2024515936 A JP2024515936 A JP 2024515936A
Authority
JP
Japan
Prior art keywords
sequence
rna
target
locus
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023556950A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022198080A5 (https=
JP2024515936A5 (https=
Inventor
トーマス，ブライアン
ブラウン，クリストファー
デヴォート，オードラ
バターフィールド，クリスティーナ
アレクサンダー，リサ
エス．，エー． ゴルツマン，ダニエラ
コスト，グレッグ
ラモット，レベッカ
エスピノサ，ディエゴ
Original Assignee
メタゲノミ，インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by メタゲノミ，インク． filed Critical メタゲノミ，インク．
Publication of JP2024515936A publication Critical patent/JP2024515936A/ja
Publication of JPWO2022198080A5 publication Critical patent/JPWO2022198080A5/ja
Publication of JP2024515936A5 publication Critical patent/JP2024515936A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/721—Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Graft Or Block Polymers (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2023556950A 2021-03-19 2022-03-18 Ｃａｓ酵素を用いたマルチプレックス編集 Pending JP2024515936A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163163510P 2021-03-19 2021-03-19
US63/163,510 2021-03-19
US202163186506P 2021-05-10 2021-05-10
US63/186,506 2021-05-10
US202163241916P 2021-09-08 2021-09-08
US63/241,916 2021-09-08
PCT/US2022/021004 WO2022198080A1 (en) 2021-03-19 2022-03-18 Multiplex editing with cas enzymes

Publications (3)

Publication Number Publication Date
JP2024515936A true JP2024515936A (ja) 2024-04-11
JPWO2022198080A5 JPWO2022198080A5 (https=) 2025-03-25
JP2024515936A5 JP2024515936A5 (https=) 2025-03-25

Family

ID=83321225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023556950A Pending JP2024515936A (ja) 2021-03-19 2022-03-18 Ｃａｓ酵素を用いたマルチプレックス編集

Country Status (9)

Country Link
US (1) US20250075233A1 (https=)
EP (1) EP4308699A4 (https=)
JP (1) JP2024515936A (https=)
KR (1) KR20230157387A (https=)
AU (1) AU2022237663A1 (https=)
BR (1) BR112023018948A2 (https=)
CA (1) CA3210361A1 (https=)
MX (1) MX2023010969A (https=)
WO (1) WO2022198080A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2617658B (en) 2020-03-06 2024-04-17 Metagenomi Inc Class II, type V CRISPR systems
KR20230021657A (ko) * 2020-05-08 2023-02-14 메타지노미, 인크. Ruvc 도메인을 포함하는 효소
BR112023014719A2 (pt) * 2021-01-22 2023-12-05 Metagenomi Inc Novas nucleases quiméricas e manipuladas
CA3225082A1 (en) 2021-08-27 2023-03-02 Brian C. Thomas Enzymes with ruvc domains
MX2024006257A (es) 2021-11-24 2024-07-29 Metagenomi Inc Sistemas de endonucleasas.
CA3277009A1 (en) * 2022-12-16 2024-06-20 Life Edit Therapeutics, Inc. RNA GUIDELINES TARGETING THE TRAC GENE AND METHODS OF USE

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525829A (ja) * 2002-05-20 2005-09-02 ファルマシア・コーポレーション 糖質コルチコイド受容体発現のアンチセンス調節
JP2018520648A (ja) * 2015-05-13 2018-08-02 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート 初代細胞におけるエンドヌクレアーゼに基づいた遺伝子編集の向上
JP2019507599A (ja) * 2016-03-04 2019-03-22 エディタス・メディシン、インコーポレイテッド がん免疫療法のためのｃｒｉｓｐｒ−ｃｐｆ１関連方法、組成物および構成要素
US20190241911A1 (en) * 2018-02-06 2019-08-08 Ohio State Innovation Foundation Engineered guide rna and uses thereof
WO2019152519A1 (en) * 2018-01-30 2019-08-08 Editas Medicine, Inc. Systems and methods for modulating chromosomal rearrangements
WO2019157324A1 (en) * 2018-02-08 2019-08-15 Sangamo Therapeutics, Inc. Engineered target specific nucleases
JP2019176869A (ja) * 2013-05-13 2019-10-17 セレクティスＣｅｌｌｅｃｔｉｓ 免疫療法のために同種異系かつ高活性のｔ細胞を操作するための方法
JP2020519277A (ja) * 2017-05-12 2020-07-02 クリスパー セラピューティクス アクチェンゲゼルシャフト 細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
WO2020168291A1 (en) * 2019-02-14 2020-08-20 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
WO2020185867A1 (en) * 2019-03-11 2020-09-17 Sorrento Therapeutics, Inc. Improved process for integration of dna constructs using rna-guided endonucleases
JP2020534869A (ja) * 2017-09-18 2020-12-03 博雅▲輯▼因（北京）生物科技有限公司Ｅｄｉｇｅｎｅ Ｉｎｃ． 遺伝子編集ｔ細胞及びその使用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10913941B2 (en) * 2019-02-14 2021-02-09 Metagenomi Ip Technologies, Llc Enzymes with RuvC domains
GB201907733D0 (en) * 2019-05-31 2019-07-17 Governing Council Of The Univ Of Toronto Methods and compositions for multiplex gene editing

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005525829A (ja) * 2002-05-20 2005-09-02 ファルマシア・コーポレーション 糖質コルチコイド受容体発現のアンチセンス調節
JP2019176869A (ja) * 2013-05-13 2019-10-17 セレクティスＣｅｌｌｅｃｔｉｓ 免疫療法のために同種異系かつ高活性のｔ細胞を操作するための方法
JP2018520648A (ja) * 2015-05-13 2018-08-02 シアトル チルドレンズ ホスピタル， ディービーエー シアトル チルドレンズ リサーチ インスティテュート 初代細胞におけるエンドヌクレアーゼに基づいた遺伝子編集の向上
JP2019507599A (ja) * 2016-03-04 2019-03-22 エディタス・メディシン、インコーポレイテッド がん免疫療法のためのｃｒｉｓｐｒ−ｃｐｆ１関連方法、組成物および構成要素
JP2020519277A (ja) * 2017-05-12 2020-07-02 クリスパー セラピューティクス アクチェンゲゼルシャフト 細胞の操作のための材料及び方法並びに免疫腫瘍学におけるその使用
JP2020534869A (ja) * 2017-09-18 2020-12-03 博雅▲輯▼因（北京）生物科技有限公司Ｅｄｉｇｅｎｅ Ｉｎｃ． 遺伝子編集ｔ細胞及びその使用
WO2019152519A1 (en) * 2018-01-30 2019-08-08 Editas Medicine, Inc. Systems and methods for modulating chromosomal rearrangements
US20190241911A1 (en) * 2018-02-06 2019-08-08 Ohio State Innovation Foundation Engineered guide rna and uses thereof
WO2019157324A1 (en) * 2018-02-08 2019-08-15 Sangamo Therapeutics, Inc. Engineered target specific nucleases
WO2020168291A1 (en) * 2019-02-14 2020-08-20 Metagenomi Ip Technologies, Llc Enzymes with ruvc domains
WO2020185867A1 (en) * 2019-03-11 2020-09-17 Sorrento Therapeutics, Inc. Improved process for integration of dna constructs using rna-guided endonucleases

Also Published As

Publication number Publication date
WO2022198080A1 (en) 2022-09-22
KR20230157387A (ko) 2023-11-16
MX2023010969A (es) 2023-09-27
CA3210361A1 (en) 2022-09-22
AU2022237663A1 (en) 2023-10-12
US20250075233A1 (en) 2025-03-06
EP4308699A1 (en) 2024-01-24
EP4308699A4 (en) 2025-12-31
AU2022237663A9 (en) 2023-10-26
BR112023018948A2 (pt) 2023-10-17

Similar Documents

Publication Publication Date Title
US20250075233A1 (en) Multiplex editing with cas enzymes
CN109843915B (zh) 基因工程化细胞及其制备方法
EP3359184B1 (en) Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
KR102587132B1 (ko) 암 면역요법을 위한 crispr-cpf1-관련 방법, 조성물 및 구성성분
JP2025060673A (ja) クラスｉｉのｖ型ｃｒｉｓｐｒ系
KR20230003467A (ko) 지시된 게놈 편집을 위한 방법 및 조성물
JP7471289B2 (ja) 抗ｌｉｖ１免疫細胞癌療法
US20240287453A1 (en) Persistent allogeneic modified immune cells and methods of use thereof
KR102151065B1 (ko) 동물 배아의 염기 교정용 조성물 및 염기 교정 방법
JP2024535672A (ja) クラスｉｉ、ｖ型ｃｒｉｓｐｒ系
AU2018367896A1 (en) Materials and methods for engineering cells and uses thereof in immuno-oncology
US20250179481A1 (en) Compositions and methods for targeting, editing, or modifying genes
JP2024533940A (ja) Ｒｕｖｃドメインを有する酵素
JP2024522086A (ja) クラスｉｉ、ｖ型ｃｒｉｓｐｒ系
WO2023225035A2 (en) Compositions and methods for engineering cells
CA3223311A1 (en) Compositions and methods for targeting, editing or modifying human genes
JP2024501892A (ja) 新規の核酸誘導型ヌクレアーゼ
WO2023183434A2 (en) Compositions and methods for generating cells with reduced immunogenicty
CN117043327A (zh) 用cas酶进行多重编辑
JP2025508794A (ja) 融合タンパク質
HK40025281A (en) Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
HK40025281B (en) Engineered meganucleases with recognition sequences found in the human t cell receptor alpha constant region gene
HK1259673A1 (en) Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
HK1259673B (en) Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250314

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250314

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260415